Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ANIX

Anixa Biosciences Inc

Apr 13 • 04:00PM ET

2.85

+0.16 5.95 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE AFMD INO BGMS ARQT MRKR ADAP KPTI MDGL BNTC

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.32	Insider Own	5.41%	Shs Outstand	33.46M	Perf Week	10.04%
Market Cap	95.55M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	0.55%	Shs Float	31.72M	Perf Month	-0.35%
Enterprise Value	80.31M	PEG	-	EPS next Q	-0.08	Inst Own	16.89%	Short Float	3.62%	Perf Quarter	-15.68%
Income	-10.31M	P/S	-	EPS this Y	4.02%	Inst Trans	0.96%	Short Ratio	7.75	Perf Half Y	-42.07%
Sales	0.00M	P/B	6.33	EPS next Y	-1.20%	ROA	-60.39%	Short Interest	1.15M	Perf YTD	-8.65%
Book/sh	0.45	P/C	6.73	EPS next 5Y	-1.53%	ROE	-62.61%	52W High	5.46 -47.77%	Perf Year	10.47%
Cash/sh	0.42	P/FCF	-	EPS past 3/5Y	9.05% 5.67%	ROIC	-67.69%	52W Low	2.44 16.80%	Perf 3Y	-50.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.56% 6.94%	Perf 5Y	-39.49%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	19.02%	Oper. Margin	-	ATR (14)	0.18	Perf 10Y	9.20%
Dividend Ex-Date	-	Quick Ratio	12.18	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	55.53	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.18	EPS Q/Q	21.94%	SMA20	6.26%	Beta	0.58	Target Price	10.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	0.86%	Rel Volume	0.83	Prev Close	2.69
Employees	4	LT Debt/Eq	0.01	Earnings	Mar 13	SMA200	-15.76%	Avg Volume	148.38K	Price	2.85
IPO	Oct 07, 1983	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	123,140	Change	5.95%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-21-25	Initiated	Maxim Group	Buy	$10
Dec-23-22	Initiated	Chardan Capital Markets	Buy	$8
Apr-12-21	Initiated	H.C. Wainwright	Buy	$11

Apr-09-26 09:05AM	Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 (PR Newswire)
Apr-07-26 08:55AM	Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 (PR Newswire)
Apr-06-26 09:10AM	Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs (PR Newswire)
Apr-01-26 08:50AM	Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing (PR Newswire) +5.43%
Mar-30-26 09:05AM	Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer (PR Newswire)
10:38AM	Loading…
Mar-12-26 10:38AM	Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast (PR Newswire)
Mar-09-26 08:30AM	Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Mar-02-26 09:10AM	Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress (PR Newswire)
Feb-23-26 08:55AM	Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat (PR Newswire)
Feb-10-26 03:50PM	Anixa Biosciences CEO Calls 2026 Pivotal as Breast Cancer Vaccine, Ovarian CAR-T Advance (MarketBeat)
Feb-09-26 08:00AM	Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation (PR Newswire)
07:31AM	EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues (Benzinga)
Feb-02-26 09:00AM	Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization (PR Newswire)
Jan-27-26 08:30AM	Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Dec-15-25 08:45AM	Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic (PR Newswire) -8.94%
09:00AM	Loading…
Dec-10-25 09:00AM	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 (PR Newswire)
Nov-17-25 08:15AM	Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization (PR Newswire)
Nov-12-25 09:00AM	Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s (PR Newswire)
Nov-10-25 10:30AM	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 (PR Newswire)
Nov-05-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:55AM	Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic (PR Newswire)
Oct-23-25 08:45AM	Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference (PR Newswire)
Oct-20-25 08:25AM	Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Oct-17-25 12:00PM	Are You Looking for a Top Momentum Pick? Why ANIXA BIOSCIENCES INC (ANIX) is a Great Choice (Zacks) -6.82%
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire) +8.03%
Oct-07-25 08:30AM	Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial (PR Newswire) +26.46%
Oct-02-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
Sep-22-25 08:05AM	Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium (PR Newswire) +5.76%
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
09:40AM	Is Solventum Corporation (SOLV) Stock Outpacing Its Medical Peers This Year? (Zacks)
06:45PM	Loading…
Sep-09-25 06:45PM	3 Under-the-Radar Biotechs Under $5 That Could Soar 200% (MarketBeat)
Sep-08-25 08:00AM	Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival (PR Newswire)
Sep-02-25 08:54AM	Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-25-25 09:13AM	Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-20-25 08:37AM	Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Aug-18-25 09:00AM	Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Aug-12-25 08:05AM	Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology (PR Newswire)
Aug-08-25 09:15AM	Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference (PR Newswire)
Aug-04-25 08:45AM	Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial (PR Newswire) +8.31%
Jul-30-25 08:15AM	Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Jul-25-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-24-25 08:00AM	Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s (PR Newswire)
Jul-09-25 09:40AM	Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology (PR Newswire)
Jun-26-25 12:00PM	ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy? (Zacks)
Jun-23-25 09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks)
08:00AM	Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Jun-20-25 07:30AM	Anixa Biosciences to Host an Investor Webcast on June 26, 2025 (PR Newswire)
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire) +5.42%
Jun-10-25 12:00PM	What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now? (Zacks)
07:00AM	Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage (PR Newswire)
Jun-09-25 08:00AM	Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 (PR Newswire) +23.19%
Jun-05-25 12:00PM	All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy (Zacks)
09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks)
Jun-03-25 07:25AM	Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview (PR Newswire)
Jun-02-25 07:00AM	Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine (PR Newswire) +12.45%
May-19-25 08:00AM	Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones (PR Newswire)
May-12-25 08:00AM	Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
Apr-30-25 08:00AM	Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th (PR Newswire)
Apr-14-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio (PR Newswire)
Apr-11-25 09:40AM	Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-10-25 09:58AM	ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up (Zacks)
Apr-09-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology (PR Newswire) +13.03%
07:45AM	EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent (Benzinga)
Apr-01-25 08:00AM	Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th (PR Newswire)
Mar-25-25 08:00AM	Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines (PR Newswire)
07:51AM	EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines (Benzinga)
Mar-24-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine (PR Newswire)
07:46AM	EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine (Benzinga)
Mar-17-25 08:00AM	Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th (PR Newswire)
Mar-10-25 08:30AM	Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties (PR Newswire) -7.39%
Mar-03-25 08:00AM	Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th (PR Newswire) -9.84%
Feb-26-25 08:00AM	Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Feb-25-25 07:30AM	Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' 'America Reports' (PR Newswire)
Feb-24-25 08:00AM	Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer (PR Newswire) -6.49%
Feb-18-25 08:00AM	Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Feb-14-25 07:00AM	Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview (PR Newswire)
Feb-11-25 08:30AM	Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum (PR Newswire)
Feb-04-25 08:30AM	Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention (PR Newswire) +6.07%
Jan-21-25 08:30AM	Anixa Biosciences CEO Provides Letter to Shareholders (PR Newswire) +16.60%
Dec-06-24 08:30AM	iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024 (ACCESS Newswire)
Dec-04-24 08:30AM	Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 (PR Newswire)
Nov-22-24 08:15AM	Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset (PR Newswire)
Nov-18-24 08:20AM	Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Nov-08-24 01:17PM	Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
Nov-06-24 08:30AM	Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
Oct-31-24 08:15AM	Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 (PR Newswire)
Oct-28-24 08:30AM	Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire) +22.15%
Oct-16-24 05:42AM	Anixa Biosciences administers second CAR-T dose in ovarian cancer trial (Clinical Trials Arena)
Oct-15-24 09:00AM	Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Oct-07-24 08:30AM	Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development (PR Newswire)
Sep-30-24 08:30AM	Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial (PR Newswire)
Sep-25-24 04:52AM	Anixa announces plans to launch Phase II breast cancer vaccine trial (Clinical Trials Arena) -6.80%
Sep-24-24 08:30AM	Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine (PR Newswire)
Sep-18-24 08:30AM	Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference (PR Newswire)
Sep-03-24 08:30AM	Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium (PR Newswire)
Aug-26-24 08:30AM	Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +6.29%
Jul-29-24 08:45AM	Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting (PR Newswire)
Jul-23-24 08:15AM	Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy (PR Newswire) -7.67%
07:45AM	EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy (Benzinga)

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The Other segment refers to its legacy operations, including patent licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Baskies Arnold M	Director	Jan 28 '26	Buy	3.04	10,000	30,400	135,000	Jan 29 08:58 AM
Titterton Lewis H jr	Director	Dec 15 '25	Option Exercise	2.92	16,000	46,720	969,334	Dec 16 08:56 AM
KUMAR AMIT	Chief Executive Officer	Oct 30 '25	Option Exercise	2.92	200,000	584,000	779,925	Oct 31 09:13 AM
Titterton Lewis H jr	Director	Jul 31 '25	Buy	3.08	10,000	30,800	953,334	Aug 04 09:00 AM
KUMAR AMIT	Chief Executive Officer	Jul 30 '25	Buy	3.16	5,000	15,800	579,925	Jul 31 09:00 AM
Baskies Arnold M	Director	Jul 18 '25	Buy	3.39	5,000	16,950	125,000	Jul 21 08:30 AM
Titterton Lewis H jr	Director	Jul 11 '25	Buy	3.14	10,000	31,400	943,334	Jul 15 06:03 AM
KUMAR AMIT	Chief Executive Officer	Jul 11 '25	Buy	3.15	5,000	15,750	574,925	Jul 14 08:40 AM
KUMAR AMIT	Chief Executive Officer	Jun 04 '25	Buy	2.85	10,000	28,500	569,925	Jun 05 09:11 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANIX

Anixa Biosciences Inc

Upgrade your Finviz experience